Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Lignende værker

• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
  af: Schiff, Michael, et al.
  Udgivet: (2014)
• Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
  af: Fleischmann, Roy, et al.
  Udgivet: (2019)
• Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
  af: Fleischmann, Roy, et al.
  Udgivet: (2016)
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
  af: Weinblatt, Michael E, et al.
  Udgivet: (2013)
• Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
  af: Schiff, Michael, et al.
  Udgivet: (2016)